TOPICS
2024/11/07
２１世紀におけるゼブラフィッシュ創薬のグローバル展開
2024/10/25
AIDXゼブラフィッシュ創薬のグローバル展開
2024/10/15
三重大学大学院システムズ薬理学の展開
2024/10/05
システムズ薬理学大学院大募集中です。
2024/09/10
Zebrafish-Based Oncocardionephrology
》oncocardiology of sorafenib
2023/04/28
Oncocardiology is a subspecialty of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular complications caused by cancer therapies. Sorafenib is a tyrosine kinase inhibitor that is used to treat advanced hepatocellular carcinoma and renal cell carcinoma. However, sorafenib can also induce cardiotoxicity, such as hypertension, left ventricular dysfunction, heart failure and ischemia. The characterization of oncocardiology of sorafenib involves the identification of risk factors, biomarkers and imaging modalities that can help to monitor and manage the cardiac effects of this drug. Additionally, the characterization of oncocardiology of sorafenib requires the development of strategies to prevent or mitigate cardiotoxicity, such as dose adjustment, drug interruption or discontinuation, and the use of cardioprotective agents.